Trial reportBMC musculoskeletal disorders2026
Efficacy and safety of a novel absorbable bone wax as a hemostatic agent for periacetabular osteotomy: a prospective, randomized controlled trial.
Trial report in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Applications and Emerging Roles of Bone Wax in Orthopaedic Surgery: A Scoping Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPeriacetabular osteotomy (PAO) is a widely used procedure to treat developmental dysplasia of the hip (DDH) in adults. Traditional bone wax cannot be absorbed on the osteotomy surface when bleeding ceases. This study aimed to evaluate the hemostatic efficacy and safety of a novel absorbable bone wax for PAO.
methodsIn this prospective, randomized, single-blinded, parallel, positive-controlled clinical trial, 70 patients with DDH treated by PAO were enrolled between October 2020 and October 2022. During the operation, the novel absorbable bone wax or the conventional bone wax was used to stanch blood exudation from the osteotomy surface randomly. The primary outcome was hemostasis time. The secondary outcomes included osteotomy surface healing time, blood parameters, and absorbability of the novel bone wax. A 2-year follow-up of the enrolled patients was then conducted.
resultsThe follow-up results revealed that the hemostasis time was not significantly different between the two groups (P > 0.05). Moreover, no statistically significant differences were observed between the two groups in blood parameters tests at 3 days or 2 weeks post-surgery (P > 0.05). Telephone follow-ups at 2 and 6 weeks post-surgery identified no patients with poor wound healing or other adverse effects. Postoperative imaging demonstrated absorbability of the novel bone wax and bone healing of the pubic osteotomy.
conclusionsAbsorbable bone wax which is a novel type of bone wax material, is safe and reliable for the hemostasis of osteotomy surfaces in the human body. The results support the clinical application and popularization of this novel absorbable bone wax in surgical procedures.
trial registrationChinese Clinical Trial Registry (ChiCTR2000033242). Registered 25/05/2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.